Repositioning Candidate Details
| Candidate ID: | R0455 |
| Source ID: | DB01224 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Quetiapine |
| Synonyms: | 2-[2-(4-Dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol; Quetiapine |
| Molecular Formula: | C21H25N3O2S |
| SMILES: | OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12 |
| Structure: |
|
| DrugBank Description: | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as and . |
| CAS Number: | 111974-69-7 |
| Molecular Weight: | 383.507 |
| DrugBank Indication: | Quetiapine is used in the symptomatic treatment of schizophrenia. In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in combination with antidepressant drugs for the treatment of major depression. Some off-label uses for this drug include the management of post-traumatic stress disorder (PTSD), generalized anxiety disorder, and psychosis associated with Parkinson's disease. |
| DrugBank Pharmacology: | Quetiapine improves the positive and negative symptoms of schizophrenia and major depression by acting on various neurotransmitter receptors, such as the serotonin and dopamine receptors. In bipolar disorder, it improves both depressive and manic symptoms. **A note on suicidality in young patients and administration in the elderly** Quetiapine can cause suicidal thinking or behavior in children and adolescents and should not be given to children under 10 years of age. It is important to monitor for suicidality if this drug is given to younger patients. In addition, this drug is not indicated for the treatment of psychosis related to dementia due to an increased death rate in elderly patients taking this drug. |
| DrugBank MoA: | Although the mechanism of action of quetiapine is not fully understood, several proposed mechanisms exist. In schizophrenia, its actions could occur from the antagonism of dopamine type 2 (D2) and serotonin 2A (5HT2A) receptors. In bipolar depression and major depression, quetiapine's actions may be attributed to the binding of this drug or its metabolite to the norepinephrine transporter. Additional effects of quetiapine, including somnolence, orthostatic hypotension, and anticholinergic effects, may result from the antagonism of H1 receptors, adrenergic α1 receptors, and muscarinic M1 receptors, respectively. |
| Targets: | 5-hydroxytryptamine receptor 2A antagonist; Dopamine D2 receptor antagonist; 5-hydroxytryptamine receptor 1A antagonist&partial agonist; 5-hydroxytryptamine receptor 1B ligand; 5-hydroxytryptamine receptor 1D ligand; 5-hydroxytryptamine receptor 1E ligand; 5-hydroxytryptamine receptor 2C ligand; 5-hydroxytryptamine receptor 3A ligand; 5-hydroxytryptamine receptor 6 antagonist; 5-hydroxytryptamine receptor 7 ligand; Dopamine D1 receptor antagonist; Dopamine D5 receptor ligand; Dopamine D3 receptor ligand; Dopamine D4 receptor ligand; Histamine H1 receptor antagonist; Alpha-1 adrenergic receptors antagonist; Alpha-2A adrenergic receptor antagonist; Alpha-2B adrenergic receptor antagonist; Alpha-2C adrenergic receptor antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor M2 ligand; Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M4 ligand; Muscarinic acetylcholine receptor M5 ligand |
| Inclusion Criteria: | Indication associated |
